BioSpace News Archive

GoodCell (“LifeVault Bio”), the company decoding human health to extend and improve the quality of life through technology powered by science, today announced it has filed a patent that will extend its intellectual property (IP) for quantifying risk and assessing cell quality to identify and validate indicators of COVID-19 morbidity and mortality.

Problematic substance use has devastating impacts on people, families and communities across Canada.

Lung cancer patients face challenges during pandemic, American Lung Association unites nation in support of those facing lung cancer

- Data showed approximately 1 in 3 people diagnosed with migraine take a recommended acute prescription medication for a migraine attack, while less than 1 in 5 who suffer frequent migraine attacks take a recommended preventive prescription medication - OVERCOME (Observational Survey of the Epidemiology, Treatment and Care of Migraine) aims to further understand the burden, stigma and barriers faced by people living with migraine

NantHealth Announces Eviti Product Updates to Aid Efficiency and Reporting for Payers & NaviNet Product Updates to Enhance the User Experience

Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa Labs”) today announced that the underwriters for its previously announced public offering of common stock have fully exercised their option to purchase 90,000 additional shares of Mesa Labs common stock.

Trinity Life Sciences, a leader in global life sciences solutions, introduces a new turnkey stakeholder insight research tool that evaluates the impact of COVID-19 on patient management and load, prescribing and compliance behaviors and sales detailing relative to pre-COVID times

Personalis, Inc., (Nasdaq: PSNL) a leader in advanced genomics for cancer, today announced the company’s participation at the Precision: Breast Cancer Summit, which will be held online, June 16-17, 2020.

Neovasc Inc. (“Neovasc” or the “Company”) ( NASDAQ , TSX : NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, announced today that it has closed its previously announced registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules of an aggregate of 3,883,0

The U.S. Food and Drug Administration today approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD). Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.